The Claim
In patients with atherosclerotic cardiovascular disease, maintaining a median low-density lipoprotein (LDL) cholesterol level of 56 mg/dL over a 3-year period is feasible and safe, with no significant increase in serious adverse events compared to maintaining a median LDL cholesterol of 66 mg/dL, suggesting that intensive lipid-lowering therapy targeting levels below 55 mg/dL does not compromise overall safety.
What the research says
Supports is higher
Support is ahead, but a single strong opposing study can change this.
These are independent scores, not a percentage. Higher-grade studies count more, so a single strong opposing study can outweigh several weaker ones.
For people with heart disease from clogged arteries, getting their bad cholesterol down to around 56 doesn’t cause more serious side effects than staying at 66, and it’s safe to keep it that low for at least three years.
See the scientific wording
In patients with atherosclerotic cardiovascular disease, achieving a median LDL cholesterol of 56 mg/dL over 3 years is feasible and safe, with no significant increase in serious adverse events compared to a median of 66 mg/dL, indicating that intensive lipid lowering to below 55 mg/dL does not compromise overall safety.
What the research says
1 studyStudy: Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease
The study looked at whether lowering bad cholesterol very aggressively in heart disease patients is safe and doable. It found that getting cholesterol down to around 56 mg/dL over 3 years was safe and didn’t cause more serious side effects than less aggressive lowering.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting studies
Not medical advice. For informational purposes only. Always consult a qualified healthcare professional before making health decisions.